NEW YORK: Pfizer Inc has agreed to buy Esperion Therapeutics Inc for about US$1.3bil, adding a promising experimental drug to its top-selling line of cholesterol products.
The purchase will put Pfizer in a position to have three blockbuster cholesterol medicines on the market: Lipitor, Esperions ETC-216 and Pfizers own experimental cholesterol drug, which company executives believe could top Lipitors US$10bil in annual sales.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!